Gabrielle Masson is a Writer at FierceBiotech. She focuses on a range of topics within medicine and healthcare, including pharmaceuticals, healthcare technology, and alternative medicine, with particular interests in gene therapy, immunology, and digital health. Gabrielle's work has been featured in Fierce Pharma, BioSpace, and RealClearHealth, showcasing her expertise in the evolving landscape of healthcare and science.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Based on Gabrielle's coverage attributes, she seems to be focused primarily on press releases and data citations within the healthcare and pharmaceutical sector. Her articles revolve around biotechnology, pharmaceutical industry news, biotech funding, clinical trials, and drug development.
To effectively reach out to Gabrielle Masson with a pitch or information, consider providing well-researched data-backed insights related to developments in the field of biotechnology and pharmaceuticals. Additionally, experts who can offer commentary or analysis backed by credible sources may find her receptive.
As Gabrielle's geographic focus is not specified but given the nature of her topics covered which are often global in scope such as clinical trials and drug development it would be beneficial for pitches to reflect an international perspective when relevant.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Gabrielle Masson
Eli Lilly's latest manufacturing expansion will support production of obesity blockbusters and next-gen assets, while the new Lilly Lebanon Advanced Therapies site will take experimental genetic medicines from research to commercialization.
By: Gabrielle Masson
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
Rina-S is the last candidate standing from Genmab's $1.8 billion ProfoundBio acquisition two years ago, with the Danish drugmaker ending development of another clinical program stemming from the buyout.
Just a few days after FDA Commissioner Makary resigned, ally Tracy Beth Høeg is also leaving the agency. Her departure comes amid reports of tension over a commissioner's voucher for Sanofi's diabetes drug.
By: Gabrielle Masson
Right after reporting a major Phase 3 LAG-3 miss that has rattled analysts, Regeneron Pharmaceuticals revealed a back-loaded partnership with Parabilis Medicines aimed at adding a new drug class to its early-stage pipeline.
By: Gabrielle Masson
Analysts are extremely encouraged by Phase 2 trial results for Relay Therapeutics’ PI3KA inhibitor in treating vascular malformations (VM), prompting the biotech to eye a potential path to accelerated approval.
By: Heather-Mckenzie, Gabrielle-Masson
Fallout from the resignation of FDA Commissioner Marty Makary continues as several other senior regulators are removed from their posts; pharma's top paid CEOs make up to 358 times more than their employees; Revolution Medicine's pancreatic cancer results highlight movement in the deadly disease space; more.
Eli Lilly joins hands with Engage Bio, acquiring the DNA delivery platform developer in hopes of bolstering its genetic medicines portfolio.
By: Annalee Armstrong, Jef Akst, Gabrielle Masson
Eli Lilly continues to spend its GLP-1 landfall with four new deals in the past week, including three in the vaccine space; the obesity leader also touted surgery-like results for its next-gen weight loss drug; Moderna's stock climbs on the hantavirus “fear trade”; and in oncology, all eyes are on Revolution at ASCO this week.
By: Gabrielle Masson
Riding a newfound surge of interest on infectious disease concerns, Moderna is linking up with a global vaccine foundation in hopes of developing a vaccine to slow the new surge in Ebola underway in the Congo and Uganda.
